DSIP Side Effects and Safety: The Documented Record

Updated Sep 5, 2026

Image: HealthRX.com clinical image

HealthRX.com quick answer. DSIP (delta sleep-inducing peptide, emideltide) has no FDA-approved use, and its human safety record rests on a small number of older, small studies rather than a modern safety database. The available human data point to measurable effects on ACTH secretion and on EEG/heart rate variability under anesthesia, not a documented profile of common side effects at typical use. Most of the published research is rodent or in vitro work that cannot establish human safety. In 2026, the more immediate hazard for anyone considering DSIP is not a known adverse effect but the fact that it is not FDA approved, is not on the 503A compounding list, and was rejected by an FDA advisory committee for that list in July 2026, which means unregulated sourcing carries its own risk independent of the peptide's biology.

DSIP is a nonapeptide originally studied as a sleep-modulating substance, distinct from prescription hypnotics like zolpidem or trazodone and from over-the-counter melatonin. It has never carried an FDA-approved indication for insomnia, stress, pain, or any other condition. See what DSIP is and how it's classified for background on the molecule itself.

What do the human trials actually report?

The published human literature on DSIP is thin and old. Three studies stand out:

A 1992 double-blind trial examined effects of DSIP on sleep in chronic insomniac patients. The published title confirms a controlled comparison was run in insomnia patients, but a detailed adverse-event breakdown is not available from the citation alone, and anyone relying on this study for a side-effect claim should verify the full paper before repeating specific numbers.

A 2009 anesthesiology study found that DSIP altered bispectral index, EEG, and heart rate variability when given as an adjunct to isoflurane anesthesia. This is a real signal of central nervous system and autonomic activity in surgical patients, but it describes an anesthesia-adjunct context, not everyday self-administered use, and it does not establish what happens with repeated non-surgical dosing.

A 1989 study reported reduced plasma immunoreactive ACTH following intravenous DSIP injection in humans. This is a genuine endocrine effect signal from a single small study, not a modern trial with dose-ranging or long-term follow-up. It matters because ACTH sits upstream of cortisol in the HPA axis; a separate line of endocrinology research shows that glucocorticoid replacement is permissive for REM sleep and sleep consolidation in adrenal insufficiency, which underscores that HPA-axis peptides and sleep architecture are mechanistically linked in ways that have not been mapped out for DSIP specifically. That connection is plausible background, not evidence that DSIP is safe or unsafe for people with adrenal or pituitary conditions.

Three small studies, the oldest from 1989 and the newest from 2009, is the entire human evidentiary base visible in the sources supporting this page. That is not enough to define a side-effect profile the way an FDA label would for an approved drug. For a fuller inventory of what has and hasn't been tested, see the DSIP clinical trials history.

What did the animal and lab research add, and what it can't tell you

The bulk of the DSIP literature is rodent, in vitro, or formulation science, mostly published in Russian and Ukrainian journals over the past decade. These studies looked at oxidative stress and antioxidant enzyme expression during physiological aging in rats (tissue antioxidant status, antioxidant enzyme gene expression), lysosomal and mitochondrial effects in aging rat tissue (lysosomal membranes, mitochondrial electron transport chain), metabolic effects during aging (metabolic effects in aging rats), hepatocyte function under foot-shock stress (rat hepatocyte function under stress), hippocampal neuronal activity (hippocampal activity in rats), blood adaptive reactions in patients with chronic brain ischemia undergoing stress-modulating therapy (blood adaptive reactions in chronic brain ischemia), and immune parameters in rats given a related compound alongside melatonin (deltaran and melatonin in experimental contact dermatitis).

A few points of caution here. First, this is animal and small-clinical-context research, not evidence that generalizes to healthy adults self-administering DSIP for sleep. Second, some studies use named products like deltaran, deltalycin, or deltalicin, or compare DSIP to a related oligopeptide called KND (comparative biological properties of KND versus DSIP); these are not necessarily interchangeable with DSIP itself, and treating them as identical would be an overreach. Two studies on diabetic retinopathy used deltalycin or deltalicin specifically, not DSIP by that name (deltalycin and retinal recovery after photostress, deltalicin in diabetic retinopathy), so they should not be read as DSIP evidence without confirming the compounds are the same. Third, formulation studies on hydrogel and polymer matrix entrapment of DSIP describe drug-delivery chemistry, not clinical safety (hydrogel entrapment and release, charged macroporous matrix entrapment). A separate review on peptides crossing the blood-brain barrier is useful background on why route and formulation affect central exposure generally, but it is not DSIP-specific safety data (peptides and the blood-brain barrier).

For a structured walk-through of how strong each category of DSIP evidence actually is, see the DSIP evidence quality assessment.

What is established, what is plausible, and what is not established

Established: DSIP has measurable biological activity in humans at the level of the HPA axis and CNS/autonomic markers under anesthesia, based on small older studies. It has no FDA-approved indication.

Plausible but unproven: that these acute, single-dose or surgical-context effects translate into a predictable, tolerable side-effect profile with repeated self-administered dosing outside a clinical setting. That animal findings on oxidative stress and aging biology have any comparable relevance in humans.

Not established: a modern dose-ranging human safety trial, a defined common-adverse-event list, drug interaction data, long-term safety data, or safety data in pregnancy, in people with adrenal or pituitary disease, or in combination with other sleep aids or hormonal therapies.

Why sourcing, not biology, is the sharper practical risk right now

DSIP has no FDA-approved application (04/22/2026 content current, per the FDA Category 2 bulk substances page). Its earlier FDA Category 2 nomination was withdrawn by the nominators, and withdrawal is not the same as approval or clearance; DSIP is not on the FDA's 503A bulk drug substances list, and no enforcement discretion currently covers compounding it (per the 503A bulk substances framework). On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee considered emideltide (DSIP) for that 503A list and voted against recommending it (per the meeting page). There is no regulatory momentum toward approval; the committee's action moved in the opposite direction.

Practically, this means any DSIP product on the market is not manufactured, tested, or labeled under FDA oversight in the way an approved drug or a legitimately compounded 503A substance would be. Given how thin the underlying human safety data already are, adding an unregulated supply chain on top compounds the uncertainty rather than resolving it. For the fuller regulatory picture, see the DSIP FDA status page and the FDA Peptide Status Tracker. For sourcing-specific considerations, see how people are obtaining DSIP.

When does this warrant urgent care rather than self-monitoring?

Because the strongest human signal involves ACTH and HPA-axis activity, anyone with known adrenal insufficiency, pituitary disease, or a history of endocrine instability should treat DSIP as unstudied in their situation rather than assume it is neutral. New symptoms after use, such as unexplained fatigue, dizziness, fainting, marked blood pressure changes, or signs of an allergic reaction (swelling, difficulty breathing, hives), warrant urgent medical evaluation rather than waiting to see if symptoms resolve. This is not a substitute for individualized medical advice, and it does not establish a specific dosing or monitoring protocol, since none has been validated in the literature reviewed here.

Evidence-to-hazard map: what each study type can and cannot tell a prospective user

Evidence type	What it shows	What it cannot show	Practical read for someone considering DSIP
Small human trials (1989-2009)	Real biological activity: reduced ACTH after IV dosing, altered EEG/HRV/BIS under anesthesia, a controlled insomnia comparison	Common side-effect rates, long-term safety, safe dosing range, interaction risk	Treat any claimed "typical side effect" list as unverified until traced to a primary source
Rodent and in vitro studies	Mechanistic hypotheses in aging, oxidative stress, hepatocyte and neuronal biology	Human relevance, human dosing, human safety thresholds	Useful for researchers formulating hypotheses, not for personal risk assessment
Named analogs (deltaran, deltalycin, deltalicin, KND)	Effects of related but distinct compounds	That DSIP itself behaves identically	Do not assume interchangeability without confirming the exact compound studied
Formulation/delivery studies (hydrogels, matrices)	Chemistry of how DSIP might be entrapped or released	Whether any resulting product is safe or effective in humans	Formulation research is not a substitute for a safety trial
FDA regulatory record	No approved indication, withdrawn nomination, rejection from the 503A list in July 2026	Nothing about safety directly, but defines the legal and quality-control context	The absence of oversight is itself a risk factor layered on top of thin biological data

Frequently asked questions

Is DSIP safe for regular use? No trial in the available record has established a safety profile for regular, ongoing self-administration. The human studies are single-dose or short-course, decades old, and small.

Are the rodent studies a reason for optimism about human use? They generate hypotheses worth testing, but rodent oxidative-stress or aging biology does not establish human safety or effectiveness, and none of these studies were designed to detect the kind of adverse effects a regulatory safety trial would look for.

Does the FDA committee's 2026 review mean approval is coming? No. The committee voted against recommending emideltide (DSIP) for the 503A bulk substances list. That is a rejection, not a step toward approval, and DSIP remains without any FDA-approved use.